Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
Jørgen Vestbo, Suzanne S. Hurd, Alvar G.N. Agustí, Paul Jones, Claus Franz Vogelmeier, Antonio Anzueto, Peter John Barnes, Leonardo Michele Fabbri, Fernando J. Martínez, Masaharu Nishimura, Robert Andrew Stockley, Don D. Sin, Roberto Rodriguez‐Roisin
American Journal of Respiratory and Critical Care Medicine · 2012 · 16,082 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P., Vogelmeier, C. F., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martínez, F. J., Nishimura, M., Stockley, R. A., Sin, D. D., & Rodriguez‐Roisin, R. (2012). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 187(4), 347–365. https://doi.org/10.1164/rccm.201204-0596pp
In text: (Vestbo et al., 2012)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy document for the diagnosis and management of COPD. This executive summary presents the main contents of the second 5-year revision of the GOLD document that has implemented some of the vast knowledge about COPD accumulated over the last years. Today, GOLD recommends that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation. The document highlights that the assessment of the patient with COPD should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities. The first three points can be used to evaluate level of symptoms and risk of future exacerbations, and this is done in a way that splits patients with COPD into four categories-A, B, C, and D. Nonpharmacologic and pharmacologic management of COPD match this assessment in an evidence-based attempt to relieve symptoms and reduce risk of exacerbations. Identification and treatment of comorbidities must have high priority, and a separate section in the document addresses management of comorbidities as well as COPD in the presence of comorbidities. The revised document also contains a new section on exacerbations of COPD. The GOLD initiative will continue to bring COPD to the attention of all relevant shareholders and will hopefully inspire future national and local guidelines on the management of COPD.
Related papers
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations2012
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2007
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*2008
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper2004
- Spirometric Reference Values from a Sample of the General U.S. Population1999
Metadata from OpenAlex (CC0). Citations are generated from the published record.